Treatment with aflibercept
CMT
STERILE
Intravitreal aflibercept was administered in a designated treatment facility under sterile conditions as per local site practices. The injection eye was anaesthetised with topical drops and subconjunctival 2% lidocaine. Aflibercept (2 mg/0.05 ml) was injected into the vitreous 4 mm posterior to the limbus using a 30 G needle.The patient was reviewed four weeks later, and treatment continued following a T&E protocol. Treatment intervals were extended by 4 weeks if VA was ≥84 letters (Snellen equivalent 6/6) or CMT was ≤300 microns. If the treatment interval was greater than 4 weeks but VA was <84 letters or OCT macular thickness was >300 microns, an aflibercept injection was given and the next follow-up interval reduced by 4 weeks.